Sanders Morris Harris LLC Uni Qure N.V. Transaction History

Sanders Morris Harris LLC

$585 Million
Q3 2024

A detailed history of Sanders Morris Harris LLC transactions in Uni Qure N.V. stock. As of the latest transaction made, Sanders Morris Harris LLC holds 68,070 shares of QURE stock, worth $942,769. This represents 0.06% of its overall portfolio holdings.

Number of Shares

68,070

Previous 68,070 -0.0%

Holding current value

$942,769

Previous $304,000 10.2%

% of portfolio

0.06%

Previous 0.05%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 10, 2024	SELL	$5.63 - $8.27 $1.69 Million - $2.48 Million	-300,025 Reduced 81.51%	68,070 $460,000
Q3 2023 Oct 13, 2023	BUY	$6.71 - $11.83 $2.47 Million - $4.35 Million	368,095 New	368,095 $2.47 Million
Q2 2023 Jul 10, 2023	BUY	$11.12 - $22.2 $756,938 - $1.51 Million	68,070 New	68,070 $780,000
Q2 2021 Jul 13, 2021	SELL	$29.97 - $37.17 $149,850 - $185,850	-5,000 Reduced 6.84%	68,070 $2 Million
Q4 2020 Jan 26, 2021	SELL	$35.35 - $50.67 $2.66 Million - $3.81 Million	-75,197 Reduced 50.72%	73,070 $2.78 Million
Q3 2020 Oct 16, 2020	BUY	$35.98 - $47.66 $5.33 Million - $7.07 Million	148,267 New	148,267 $5.41 Million
Q2 2020 Jul 09, 2020	SELL	$45.06 - $67.74 $3.2 Million - $4.81 Million	-71,000 Closed	0 $0
Q1 2020 Apr 09, 2020	BUY	$40.01 - $73.97 $1.02 Million - $1.89 Million	25,600 Added 56.39%	71,000 $4.3 Million
Q4 2019 Jan 09, 2020	SELL	$37.13 - $74.62 $2.83 Million - $5.69 Million	-76,205 Reduced 62.67%	45,400 $3.19 Million
Q3 2019 Nov 14, 2019	BUY	$39.36 - $76.8 $3.21 Million - $6.26 Million	81,505 Added 203.25%	121,605 $4.66 Million
Q2 2019 Jul 10, 2019	BUY	$52.76 - $82.19 $2.12 Million - $3.3 Million	40,100 New	40,100 $3.08 Million

Others Institutions Holding QURE

# of Institutions

154

Shares Held

41M

Call Options Held

925K

Put Options Held

617K

View Full List

About uniQure N.V.

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $647M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

More about QURE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sanders Morris Harris LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sanders Morris Harris LLC with notifications on news.

Account

Sanders Morris Harris LLC Uni Qure N.V. Transaction History